V

Vivo Capital

78 employees

Vivo is a global investment firm focused on healthcare with approximately $5.8 billion in AUM

Investor insights

Countries invested in

united states2

Sectors invested in

Biotechnology116
Health Care97
Pharmaceutical62
Medical51
Therapeutics44
Biopharma28
Medical Device21
Life Science16
Manufacturing7
Wellness6
Health Diagnostics6
Oncology6
Gene Therapy6
biotechnology6
Acne5
Genetics5
Robotics4
Neuroscience4
Gene Editing4
Clinical development4

Funding rounds participated in

$25M sweet spot round size

Most of their 175 investments are in rounds between $28M and $84M

Investor type

Private Equity Firm
Venture Capital

Basic info

Industry

financial services

Sectors

Financial Services
Health Care
Finance
Venture Capital

Date founded

1996

Investments made

O

Olema Oncology raised $130M on September 5, 2023

Investors: Logos Global Management, LP, Lightspeed Venture Partners, Woodline Partners LP and Vivo Capital

瑞龙诺赋(上海)医疗科技有限公司 raised $27M on August 30, 2023

Investors: GGV Capital, Lilly Asia Ventures, 经纬创投(北京)投资管理顾问有限公司 and Vivo Capital

C

COMPASS Pathways raised $125M on August 16, 2023

Investors: Soleus Capital Management, L.P., Laurion Capital Management LP, Partner Fund Management, RA Capital Management, L.P., Surveyor Capital, Logos Global Management, LP, TCG X, Armistice Capital LLC and Vivo Capital

I

Icosavax, Inc. raised $68M on May 22, 2023

Investors: Logos Global Management, LP, TCG X and Vivo Capital

D

Delcath Systems, Inc raised $85M on March 27, 2023

Investors: Logos Global Management, LP and Vivo Capital

E

EpiBiologics raised $50M on March 22, 2023

Investors: Polaris Partners, GV and Vivo Capital

U

Unicycive Therapeutics raised $30M on March 6, 2023

Investors: Logos Global Management, LP, RA Capital Management, L.P. and Vivo Capital

瑞龙诺赋(上海)医疗科技有限公司 raised undisclosed on December 21, 2022

Investors: 经纬创投(北京)投资管理顾问有限公司, Lilly Asia Ventures, GGV Capital and Vivo Capital

P

PULMOCIDE LIMITED raised $52M on December 6, 2022

Investors: 旭化成ファーマ(株), JEITO, F-Prime Capital Partners, S.R. One Ltd, Longwood Fund, IP Group plc, SV Life Sciences and Vivo Capital

R

Rgenta Therapeutics Inc. raised $52M on November 29, 2022

Investors: 经纬创投(北京)投资管理顾问有限公司, Delos Capital, Lilly Asia Ventures, 凯泰资本, 中金公司, Lengend Star and Vivo Capital

FAQ